Article Text

other Versions

PDF
Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690,550, an orally active Janus kinase (JAK)inhibitor: results from a randomized, double-blind, placebo-controlled trial
  1. John H Coombs
  1. Pfizer Inc, Ann Arbor, Michigan, United States
    1. Bradley J Bloom
    1. Pfizer Inc, New London, Connecticut, United States
      1. Ferdinand C Breedveld
      1. Leiden University Medical Centre, Leiden, Netherlands
        1. Mark P Fletcher
        1. Pfizer Inc, Ann Arbor, Michigan, United States
          1. David Gruben
          1. Pfizer Inc, New London, Connecticut, United States
            1. Joel M Kremer
            1. Albany Medical College, Albany, New York, United States
              1. Ruben Burgos-Vargas
              1. Hospital General de Mexico, Mexico City, Mexico
                1. Bethanie Wilkinson
                1. Pfizer Inc, New London, Connecticut, United States
                  1. Cristiano A F Zerbini
                  1. Hospital Heliopolis, Sao Paulo, Brazil
                    1. Samuel H Zwillich (samuel.h.zwillich{at}pfizer.com)
                    1. Pfizer Inc, Ann Arbor, Michigan, United States

                      Abstract

                      Objectives: To determine the efficacy of CP-690,550 in improving pain, function, and health status in patients with moderate to severe active rheumatoid arthritis (RA) and an inadequate response to methotrexate or a TNF-α inhibitor.

                      Methods: Patients were randomized equally to placebo, CP 690,550 5, 15, or 30 mg BID for 6 weeks, with 6 weeks' follow-up. Patient's Assessment of Arthritis Pain (Pain), Patient's Assessment of Disease Activity, HAQ-DI, and SF-36 were recorded.

                      Results: At Week 6, significantly more patients in the CP-690,550 5, 15, and 30 mg BID groups experienced a 50% improvement in pain compared with placebo (44%, 66%, 78%, and 14%, respectively), clinically meaningful reductions in HAQ-DI (≥0.3 units) [57%, 75%, 76%, and 36%, respectively], and clinically meaningful improvements in SF-36 domains and physical and mental components.

                      Conclusions: CP-690,550 was efficacious in improving the pain, function, and health status of patients with RA, from Week 1 to Week 6.

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.